Ghayas Issa
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ghayas Issa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:30 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06769490 · Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT06629584 · Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Malignant Solid Tumors · principal investigator
- Ph1/Ph2NCT06284486 · A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT06229912 · A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX GenesM.D. Anderson Cancer Center · recruiting · Leukemia, HOX Gene · principal investigator
- Ph1/Ph2NCT05360160 · A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)M.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT02286726 · CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid LeukemiaM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:30 UTC. The ranking covers the 200 most relevant of 47 PubMed records, and a shared surname and initials can bring in a namesake. All 47 on PubMed
- 475 citationsRCR 40.0
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol · 2021297 citationsRCR 16.3
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.Lancet Haematol · 2023236 citationsRCR 20.8
- Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).J Clin Oncol · 2025236 citationsRCR 60.4
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.J Clin Oncol · 2024179 citationsRCR 23.4
- 171 citationsRCR 5.6
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.N Engl J Med · 2024156 citationsRCR 21.1
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.Blood Cancer J · 2021120 citationsRCR 6.8
- Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.Lancet Oncol · 2024117 citationsRCR 14.5